Study Of Pharmacogenetic Risk Factors For Avascular Necrosis CCG 1882
- Identify possible pharmacogenetic risk factors for avascular necrosis (AVN) in
pediatric patients who received intensive therapy for acute lymphoblastic leukemia on
clinical trial CCG-1882.
- Compare whether thymidylate synthase 2/2 enhancer repeat genotype and vitamin D
receptor C/C start site genotype are more common among patients who developed AVN than
among patients who did not.
OUTLINE: This is a retrospective, cohort, multicenter study. Patients are stratified
according to gender and treatment regimen on clinical trial CCG-1882 (augmented vs regular
DNA is extracted from slides of blast samples that were previously obtained from patients
treated on clinical trial CCG-1882. DNA genotyping is performed, and genotypes (proportion
of population with variant alleles or frequency of variant alleles) are compared between
patients who did and did not develop avascular necrosis.
PROJECTED ACCRUAL: A total of 671 tissue samples from patients (294 females and 377 males)
will be accrued for this study.
Identification of possible pharmacogenetic risk factors for avascular necrosis
Mary Relling, PharmD
St. Jude Children's Research Hospital
United States: Federal Government